Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Gross Profit (2016 - 2025)

Heron Therapeutics' Gross Profit history spans 10 years, with the latest figure at $29.5 million for Q4 2025.

  • For Q4 2025, Gross Profit fell 3.55% year-over-year to $29.5 million; the TTM value through Dec 2025 reached $113.6 million, up 7.5%, while the annual FY2025 figure was $113.6 million, 7.5% up from the prior year.
  • Gross Profit reached $29.5 million in Q4 2025 per HRTX's latest filing, up from $26.3 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $30.6 million in Q4 2024 to a low of $193000.0 in Q2 2021.
  • Average Gross Profit over 5 years is $18.0 million, with a median of $15.3 million recorded in 2022.
  • Peak YoY movement for Gross Profit: crashed 98.59% in 2021, then skyrocketed 5835.23% in 2022.
  • A 5-year view of Gross Profit shows it stood at $9.7 million in 2021, then surged by 79.13% to $17.4 million in 2022, then skyrocketed by 39.92% to $24.3 million in 2023, then increased by 25.48% to $30.6 million in 2024, then dropped by 3.55% to $29.5 million in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Gross Profit are $29.5 million (Q4 2025), $26.3 million (Q3 2025), and $27.3 million (Q2 2025).